Stay updated on Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAn NIH announcement about its website transition appears above the 403 error page. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe footer now identifies the site as revision v3.7.1 instead of v3.7.0; the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record, replacing the expected study details. This indicates that the study content and related links are inaccessible from the public site, signaling an access restriction rather than an update to the study data.SummaryDifference21%

- Check48 days agoChange DetectedThe page revision was updated from v3.6.6 to v3.7.0, signaling a new build deployment. This change represents a backend/software version increment and does not alter the displayed study details.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page shows a new revision line: Revision: v3.6.6, replacing v3.6.5, indicating a small documentation update. This update concerns only metadata and does not alter the study details or visible content.SummaryDifference0.1%

- Check83 days agoChange DetectedRevision label updated from v3.6.4 to v3.6.5, reflecting a small maintenance update to the page and no alterations to the study details.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial page.